title: Does zoledronic acid have additive effect on suppression of plasma estrogen levels?
authors.forename: Mehmet Ali Nahit
authors.initials: MA
authors.lastname: Sendur
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.forename: Nuriye Yildirim
authors.initials: NY
authors.lastname: Ozdemir
authors.forename: Muhammed Bulent
authors.initials: MB
authors.lastname: Akinci
authors.forename: Nurullah
authors.initials: N
authors.lastname: Zengin
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D004357:Drug Synergism; D004967:Estrogens / Q000097:blood*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004967:Estrogens; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D000077211:Zoledronic Acid; D000077289:Letrozole